ATE380556T1 - Verwendung von botulinumtoxin zur herstellung eines medikaments zur behandlung der lithiasis der speicheldrüse, der gallenblase, der niere oder des pankreas - Google Patents
Verwendung von botulinumtoxin zur herstellung eines medikaments zur behandlung der lithiasis der speicheldrüse, der gallenblase, der niere oder des pankreasInfo
- Publication number
- ATE380556T1 ATE380556T1 AT05757840T AT05757840T ATE380556T1 AT E380556 T1 ATE380556 T1 AT E380556T1 AT 05757840 T AT05757840 T AT 05757840T AT 05757840 T AT05757840 T AT 05757840T AT E380556 T1 ATE380556 T1 AT E380556T1
- Authority
- AT
- Austria
- Prior art keywords
- lithiasis
- gallbladder
- pancreas
- medication
- kidney
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0415490A GB2417419A (en) | 2004-07-12 | 2004-07-12 | Therapeutic use of Botulinum toxin |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE380556T1 true ATE380556T1 (de) | 2007-12-15 |
Family
ID=32865774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05757840T ATE380556T1 (de) | 2004-07-12 | 2005-07-06 | Verwendung von botulinumtoxin zur herstellung eines medikaments zur behandlung der lithiasis der speicheldrüse, der gallenblase, der niere oder des pankreas |
Country Status (10)
Country | Link |
---|---|
US (1) | US7838009B2 (de) |
EP (1) | EP1773378B1 (de) |
JP (1) | JP4950044B2 (de) |
AR (1) | AR049977A1 (de) |
AT (1) | ATE380556T1 (de) |
CA (1) | CA2573441A1 (de) |
DE (1) | DE602005003836T2 (de) |
ES (1) | ES2297730T3 (de) |
GB (1) | GB2417419A (de) |
WO (1) | WO2006005912A2 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006096164A1 (en) | 2005-03-03 | 2006-09-14 | Allergan, Inc. | Media for clostridium bacterium and processes for obtaining a clostridial toxin |
FR2902341B1 (fr) * | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
FR2907680B1 (fr) | 2006-10-27 | 2012-12-28 | Scras | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux |
FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
ES2520765T3 (es) * | 2007-02-15 | 2014-11-11 | Allergan, Inc. | Uso de toxina botulínica para el tratamiento de hiperhidrosis |
FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
US7455845B2 (en) | 1997-07-15 | 2008-11-25 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure |
ES2247817T3 (es) * | 1998-07-06 | 2006-03-01 | Nanobac Oy | Metodo para la erradicacion de nanobacterias. |
US6143306A (en) * | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
-
2004
- 2004-07-12 GB GB0415490A patent/GB2417419A/en not_active Withdrawn
-
2005
- 2005-07-06 CA CA002573441A patent/CA2573441A1/en not_active Abandoned
- 2005-07-06 EP EP05757840A patent/EP1773378B1/de not_active Not-in-force
- 2005-07-06 DE DE602005003836T patent/DE602005003836T2/de active Active
- 2005-07-06 JP JP2007520878A patent/JP4950044B2/ja not_active Expired - Fee Related
- 2005-07-06 AT AT05757840T patent/ATE380556T1/de not_active IP Right Cessation
- 2005-07-06 WO PCT/GB2005/002659 patent/WO2006005912A2/en active Application Filing
- 2005-07-06 US US11/632,222 patent/US7838009B2/en not_active Expired - Fee Related
- 2005-07-06 ES ES05757840T patent/ES2297730T3/es active Active
- 2005-07-12 AR ARP050102875A patent/AR049977A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20080292661A1 (en) | 2008-11-27 |
EP1773378B1 (de) | 2007-12-12 |
ES2297730T3 (es) | 2008-05-01 |
JP4950044B2 (ja) | 2012-06-13 |
WO2006005912A3 (en) | 2006-04-20 |
EP1773378A2 (de) | 2007-04-18 |
GB0415490D0 (en) | 2004-08-11 |
CA2573441A1 (en) | 2006-01-19 |
WO2006005912A2 (en) | 2006-01-19 |
US7838009B2 (en) | 2010-11-23 |
DE602005003836T2 (de) | 2009-01-15 |
GB2417419A (en) | 2006-03-01 |
JP2008505962A (ja) | 2008-02-28 |
AR049977A1 (es) | 2006-09-20 |
DE602005003836D1 (de) | 2008-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005011656D1 (de) | Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin | |
NO20080217L (no) | B-celle reduksjon ved anvendelse av CD20-spesifikke bindingsmolekyler | |
ATE499004T1 (de) | Beizmittel zur bekämpfung von phytopathogenen pilzen | |
DE602006019468D1 (de) | Diarylharnstoffe zur behandlung von pulmonaler hypertonie | |
DE602006003538D1 (de) | Benzothiazol-, thiazolopyridin-, benzooxazol- und oxazolopyridin-derivate als verbindungen zur behandlung von diabetes | |
DE602006017980D1 (de) | 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie | |
ATE483009T1 (de) | Verwendung von hydrophobinen zur schmutzabweisenden behandlung von harten oberflächen | |
WO2007125501A3 (en) | Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness | |
ATE380556T1 (de) | Verwendung von botulinumtoxin zur herstellung eines medikaments zur behandlung der lithiasis der speicheldrüse, der gallenblase, der niere oder des pankreas | |
FI20050023A (fi) | Puun käsittelyaine, menetelmä puun käsittelemiseksi ja puutuote | |
ATE515261T1 (de) | Zusammensetzungen zur behandlung von diabetes | |
ATE532518T1 (de) | Dipeptidyl-peptidase-hemmer zur behandlung von diabetes | |
DE102005001078A8 (de) | Glaspulver, insbesondere biologisch aktives Glaspulver und Verfahren zur Herstellung von Glaspulver, insbesondere biologisch aktivem Glaspulver | |
ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
DE602005023877D1 (de) | Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide | |
WO2006101387A3 (en) | Method for interfering with blood coagulation by modulating cross-beta structures fibril formation | |
ATE548035T1 (de) | Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat | |
DE602006013945D1 (de) | Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck | |
DE602006017367D1 (de) | Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut | |
DE602006003094D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit | |
WO2008048121A3 (en) | Macrocyclic cysteine protease inhibitors and compositions thereof | |
WO2006132739A3 (en) | Novel chemical compounds | |
DE602005016141D1 (de) | S-mirtazapin zur behandlung von hitzewallungen | |
WO2005105842A3 (en) | Crystal structure of cytochrome p450 3a4 and uses thereof | |
DE602005027251D1 (de) | Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |